- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00983359
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Focal Therapy in the Treatment of Patients With 1-3 Brain Metastases
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
PURPOSE: This phase II trial is study how well stereotactic radiation therapy works in treating patients with brain metastases
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- To determine the neurological death rate following the initiation of conformal stereotactic radiotherapy in patients with 1-3 brain metastases.
Secondary
- To determine the overall survival rate at 6 months.
- To determine the progression-free survival rate or brain metastases recurrence rate at 6 months.
- To determine the time to neurological death, time to systemic death, and Karnofsky decay time.
- To determine the frequency and severity of adverse events associated with conformal stereotactic radiotherapy.
OUTLINE: Patients undergo conformal stereotactic radiotherapy over 5 days to an area including 3 mm around the metastases or the surgical cavity. Patients may receive additional radiotherapy if symptomatic metastases emerge at different sites.
After completion of study treatment, patients are followed up at 1 and 2 months and then every 3 months thereafter.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210-1240
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Histology-confirmed cancer with 1 to 3 symptomatic brain metastases imaged by MRI/CT scans.
- Have cancer not originating in central nervous system (CNS)
- Karnofsky score of at least 60
- Given written consent
- At least 18 years of age
Exclusion Criteria:
- Prior whole brain radiotherapy or prior focal radiotherapy of the metastasis/es considered for this trial.
- Certain radiosensitive primary tumors such as small cell lung cancer, germ cell tumors, lymphoma, leukemia or multiple myeloma.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment (conformal stereotactic radiation therapy)
Patients undergo conformal stereotatic radiation
|
Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status
Zeitfenster: Up to 5 years
|
Neurological death is defined as dying with progressive neurological dysfunction regardless of systemic disease status.
Patients wtih severe neurological disability who die of intercurrent illness will also be considered to have died of neurological death.
|
Up to 5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression-free Survival (PFS)
Zeitfenster: Up to 5 years
|
Time from enrollment to first date of progressive or recurrent disease.
Worsening of neurological symptoms is considered indicative of neurological disease progression.
Patients who die of disease-related or treatment-related causes will be considered to have progressed at their date of death; i.e., not be considered 'censored'.
PFS will be considered censored only if no progression is noted or if the patient dies of a clearly non-cancer-related event such as accident.
|
Up to 5 years
|
Time to Neurological Death
Zeitfenster: From time of enrollment up to 5 years
|
Time from enrollment to date of death directly due to brain metastases.
Deaths from other causes including hemorrhage or infection will be considered 'censored' observations in the setting of neurologic improvement or stabilization.
If the patient dies of any cause with worsening of neurologic symptoms, the death will be counted as an 'event' or neurological death.
|
From time of enrollment up to 5 years
|
Time to Systemic Death
Zeitfenster: From time of enrollment up to 5 years
|
Descriptive analysis will be conducted using Kaplan-Meier survival analysis
|
From time of enrollment up to 5 years
|
Karnofsky Decay Time
Zeitfenster: From time of enrollment up to 5 years
|
Time from enrollment to the date the patient's Karnofsky performance score drops below 60.
If the patient dies of any cause with no documentation of a drop in their Karnofsky score to less than 60, the date of death will be used as the date of worsening of the Karnofsky score.
A patient with a Karnofsky score of 60 or greater requires occasional assistance, but is able to care for most of his/her needs.
A patient's Karnofsky decay time will be considered censored if the patient is still under follow up with a Karnofsky score of 60 or greater and if the patient dies of a non-cancer-related cause.
|
From time of enrollment up to 5 years
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Mario Ammirati, MD, Ohio State University Comprehensive Cancer Center
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- OSU-06138
- NCI-2011-03139 (Registrierungskennung: Clinical Trials Reporting Program (CTRP))
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Radiation Therapy
-
Alpha Tau Medical LTD.Noch keine RekrutierungBrustkrebs | Brustkrebs | Rezidivierender BrustkrebsIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Hauttumor | Kutane MetastasenFrankreich
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTCNoch keine RekrutierungKopf-Hals-Plattenepithelkarzinom | PlattenepithelkarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungProstata-AdenokarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael
-
Alpha Tau Medical LTD.RekrutierungLungenkrebs | Wiederkehrender LungenkrebsIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael
-
Alpha Tau Medical LTD.AbgeschlossenPlattenepithelkarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaItalien
-
Alpha Tau Medical LTD.Aktiv, nicht rekrutierendHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael